Corcept Therapeutics CORT Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's shares (diluted)?
- Corcept Therapeutics (CORT) reported shares (diluted) of 104.4M in Q1 2026.
- How has Corcept Therapeutics's shares (diluted) changed year-over-year?
- Corcept Therapeutics's shares (diluted) decreased by 12.8% year-over-year, from 119.8M to 104.4M.
- What is the long-term trend for Corcept Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Corcept Therapeutics's shares (diluted) has grown at a -1.4% compound annual growth rate (CAGR), from 507.4M to 479.7M.
- What does shares (diluted) mean?
- The total number of shares that would exist if all potential stock-based instruments were converted into common shares.
- How do you interpret shares (diluted)?
- An increase suggests a higher potential for dilution, which can pressure future earnings per share. It helps investors understand the full scope of potential equity expansion from management compensation or financing activities.
- How does shares (diluted) compare across companies?
- Essential for comparing the potential equity dilution risk across companies with different levels of stock-based compensation.